title: Peripheral blood stem cell mobilization in multiple myeloma comparison of two consecutive regimens in a limited resources country.
abstract: This study compared retrospectively the effectiveness, toxicity and hematopoietic recovery after autologous peripheral blood stem cell transplantation (ASCT) of two consecutive peripheral blood stem cell mobilization regimens in newly diagnosed MM patients. Patients in group 1 (n=178) were treated with 4 g/m2of cyclophosphamide (CY) plus G-CSF (5 μg/kg/day). Patients in group 2 (n=117) with 750 mg/m2of VP16 plus G-CSF (10 μg/kg/day). Optimal mobilization, defined by a target number of 8 × 106CD34+ cells/kg collected, was achieved in 62.4% and 89.7% of patients in groups 1 and 2, respectively (P<10-4). The median number of aphaeresis sessions was reduced from two in group 1 to one in group 2 (P<10-4). Grade4neutropenia, febrile neutropenia and IV antibiotic use were significantly more frequent in group 1 than in group 2 (P<10-4). Red blood cell transfusion requirements were significantly greater in group 1 (P=0.007). The switch to VP16-G-CSF10resulted in a significant reduction of the number of hospitalization days (P<10-4). Neutrophil and platelet recovery after ASCT occurred on days 11 and 12, respectively, in the two groups with no significant differences. VP16+G-CSF10allowed liberation of resources in the clinical and aphaeresis departments and demonstrated a better effectiveness-safety profile than CY+G-CSF5.
authors: Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.|Université de Tunis El Manar, Faculté de Médecine de Tunis, Tunis, Tunisia.
authors: N
authors: N
authors: Ben Abdejlil
authors: Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.|Université de Tunis El Manar, Faculté de Médecine de Tunis, Tunis, Tunisia.
authors: D
authors: D
authors: Belloumi
authors: Centre National de Transfusion Sanguine, Tunis, Tunisia.
authors: M
authors: M
authors: Mâammar
authors: Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.|Université de Tunis El Manar, Faculté de Médecine de Tunis, Tunis, Tunisia.
authors: R
authors: R
authors: El Fatimi
authors: Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.|Université de Tunis El Manar, Faculté de Médecine de Tunis, Tunis, Tunisia.
authors: L
authors: L
authors: Torjman
authors: Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.|Université de Tunis El Manar, Faculté de Médecine de Tunis, Tunis, Tunisia.
authors: A
authors: A
authors: Lakhal
authors: Centre National de Transfusion Sanguine, Tunis, Tunisia.
authors: F
authors: F
authors: Jenhani
authors: Centre National de Transfusion Sanguine, Tunis, Tunisia.
authors: S
authors: S
authors: Hmida
authors: Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.|Université de Tunis El Manar, Faculté de Médecine de Tunis, Tunis, Tunisia.
authors: T
authors: T
authors: Ben Othman
authors: Centre National de Greffe de Moelle Osseuse de Tunis, Tunis, Tunisia.|Université de Tunis El Manar, Faculté de Médecine de Tunis, Tunis, Tunisia.
authors: S
authors: S
authors: Ladeb
mesh_terms: D000328:Adult; D000368:Aged; D064591:Allografts; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide